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Accepted 12 July 2011AbstractAlzheimer’s disease (AD) is the most common form of dementia, and one of the principal causes leading to death around the world. It is
a progressive neurodegenerative disorder that still remains without definite cure. Memantine, a licensed AD drug, is an open-channel and partial
trapping blocker that functions as a potent NMDA receptor antagonist, even at low concentrations. Aside from being uncompetitive, it also allows
near-normal physiological NMDA receptor activity throughout the brain even with high glutamate concentrations, making it more reliable and
tolerable than other AD-targeted drugs. It has also been found to be effective, safe, and well-tolerated in animal models as well as patients with
moderate-to-severeAD.Aside fromNMDAreceptor antagonism,numerous studies have reported thatmemantine canalso affect dopamine receptors,
block excessive calcium influx and production of reactive oxygen species (ROS) induced byAb oligomers, and inhibit the internal ribosome entry site
(IRES), thus preventing the expression of the amyloid precursor and tau proteins which are considered as early indicators of Alzheimer’s.
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In western countries, Alzheimer’s disease (AD) is the most
common form of dementia [1] and is the fourth leading cause
of mortality in the United States alone. In Asia, AD is the
principal cause of dementia and accounts for 50e60% of all
cases, lasting for about 3e20 years from diagnosis [2]. AD is
considered as a largely age-related brain disorder that is
progressive, fatal, and still has no current cure. Severe memory
loss, confusion, and impaired cognitive abilities characterize* Corresponding author. Department of Bioscience Technology, Chung Yuan
Christian University, Chung-Li 32023, Taiwan.
E-mail address: tywu@cycu.edu.tw (T.-Y. Wu).
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doi:10.1016/j.tjog.2011.10.004AD predominantly. It is worth noting that the global fertility
rate has dropped from 5% to 2.5%, from 1950 to 2010,
according to the U.N. population division (UNPD). Further-
more, the aging population of females in the developed
countries (Fig. 1) will make the reduction of fertility rate more
severe. For example, in Taiwan, Singapore, and South Korea,
the number of children a woman is expected to have over her
life time, is between 1.1 and 1.3. Thus, the total fertility rate in
these three countries is beneath the threshold and among the
lowest in the world. In Taiwan, the government have posted
statements like “Having a child will complete your life” and
“Who will play with me”, aimed at families with one child.
Thus, AD will be a big issue in these developed, but aging,
societies.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. The population of female in the developed countries. The data source is
from UNPD, 2011.
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a German psychiatrist and neuropathologist, reported the
curious case of one of his patients who suffered from memory
problems as well as difficulty in speaking and understanding.
The deterioration of normal cognitive functions progressed
rapidly and within a few years, his patient died from the
unknown disease. It was only a century after Alzheimer’s
discovery that scientists were able to shed light on the mystery
of its cause and identify the symptoms which mark the onset
of AD [3].
AD can be divided into four stages, characterized by
progressive cognitive and functional decline [4]. The first
stage, pre-dementia, has the most unassuming symptoms often
mistaken as age-related or stress-related. Patients with pre-
dementia often exhibit mild problems concerning executive
functions and semantic memory disruptions, while also
exhibiting a proclivity to apathy. However, patients at this
stage typically take up to 8 years of neuropsychological testing
before they are able to satisfy the clinical criteria for AD
diagnosis. A worsening of memory abilities along with subtle
agnosia and apraxia exemplify early stage dementia. Language
problems, mainly decreased word fluency, are also manifested,
and newly acquired information is more easily forgotten than
old information. In moderate dementia, advanced deterioration
slows down activity and eventually leads to inability to
perform basic functions. Loss of vocabulary, paraphasia, long-
term memory impairment, wandering, delusions, and other
neuropsychiatric changes also become apparent at this stage.
Once patients enter the final stage, or advanced dementia,
speech is completely lost although they can still reciprocate
emotion, and muscle mass and mobility thoroughly deterio-
rates until the patient becomes bedridden. AD is a terminal
illness; other factors contribute to death.
The discovery of the first mutation in the amyloid precursor
protein (APP) gene in the 1990s became the basis of the
b-amyloid cascade hypothesis. This states that familial AD
mutations result in an increased production of b-amyloid (Ab)peptides, which lead to senile plaques and dementia [5]. Most
notably, the aggregation of b-amyloid in the form of senile
plaques and the formation and fibrillization of hyper-
phosphorylated tau proteins into neurofibrillary tangles
(NFTs), are said to be responsible for much of the late-stage
cognitive decline observed in patients with AD [6]. These
defining features can be found localized in different areas, the
plaques being extracellular as they build up between nerve
cells [3] while NFTs remain intracellular, being deposited in
nerve cell bodies as well as in neurites in the neuropil [7].
Formation of plaques and tangles in the brain, blocks nerve
cell-to-cell signaling and destroys vital cellular paths where
essential nutrients and other supplies travel, respectively.
However, recent discovery of the mechanisms that lead to
neurodegeneration have vindicated Ab plaques and tau
tangles, regarding them as secondary products rather than
causative, and pinpointed oxidative stress and mitochondrial
malfunction as factors that initiate the neuronal cascade that
leads to AD instead [6]. Ab secretion has been found to have
antioxidant activity and serves to antagonize uncontrolled
oxidative stress caused by excessive generation of reactive
oxidative species (ROS) and mitochondrial anomalies, as
opposed to stimulating their production [8]. NFTs, on the other
hand, can protect against neuronal damage, as their presence
in neurons is associated with reduced steady-state Ab
production as well as reduced levels of oxidative stress [6].
Another presumed cause of AD is excitotoxicity, which is
a pathological process that damages and kills neurons due
partly to the overactivation of N-methyl-D-aspartate glutamate
(NMDA) receptors that permit excessive Ca2þ influx through
the receptor’s associated ion channel [1,6,9e11]. Over acti-
vation of NMDA receptors does not necessitate large amounts
of glutamate, the primary excitatory neurotransmitter in the
brain, but can be triggered by depolarization of neurons due to
mechanical insults or injury. Because excitotoxicity has long
been associated with the pathophysiology of acute and chronic
neurodegenerative disorders [12], it is considered as a partic-
ularly attractive target for neuroprotective efforts [1].
Memantine
Memantine, or 1-amino-3,5-dimethyladamantane hydro-
chloride, is a derivative of amantadine (1-adamantanamine
hydrochloride), an anti-viral agent that has long been used
clinically to treat Parkinson’s disease in the US and in Europe.
Aside from anti-Parkinsonian properties, it also possesses anti-
epileptic properties, and is now widely used in the treatment of
AD [13]. Memantine was first synthesized by researchers at
Eli Lilly & Co., in the hopes of developing an agent that
lowers elevated blood sugar levels, but proved to have no such
benefits. It was not until 1972 when Merz and Co. applied for
a patent that the therapeutic relevance of memantine was
discovered. They demonstrated that memantine has CNS
activity as well as a potential for treating neurodegenerative
and cerebral disorders [14]. At first, postulates regarding its
mechanism of action included direct and indirect dopami-
nergic, serotonergic, and noradrenergic activities, but they
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originally been obtained at concentrations higher than ach-
ieved therapeutically. Extensive preclinical research has since
established NMDA-receptor antagonism as the therapeutic
mechanism of action of memantine [11,14]. As early as 1989,
memantine has been known to block NMDA-induced current
in embryonic mouse spinal neurons in vitro [13]. During
therapeutic use, memantine concentrations found in the cere-
brospinal fluid suggests that its primary site of action is the
NMDA receptor, but it induces fewer and less profound effects
on perception or consciousness than drugs like PCP or ket-
amine [15]. As an uncompetitive NMDA receptor antagonist,
it has been used at therapeutic concentrations in the treatment
of dementia, and has proven itself devoid of side effects and
shown good tolerability clinically in more than 200,000
treated patients [14]. It has also been shown to be more potent
in displacing [3H]MK-801 binding in the cerebellum than in
the cortex [14,16], and like other NMDA receptor antagonists,
memantine at high concentrations can inhibit mechanisms of
synaptic plasticity that are believed to underlie learning and
memory [16, 17]. It also mimics the physiological function of
Mg2þ due to its high voltage dependency, which allows it to
exit the NMDA channel upon moderate depolarization under
pathological conditions [12]. According to a 1999 review,
other possible therapeutic applications of memantine, aside
from AD, include AIDS, glaucoma, hepatic encephalopathy,
multiple sclerosis, tinnitus, Parkinson’s disease, tardive dys-
knesia, chronic pain, tolerance, sensitization and drug addic-
tion, epilepsy, spasticity, and depression and anxiety [14].
Mechanism of action, metabolism, and pharmacokinetic
profile
Over the years, research regarding the mechanism of action
of memantine has improved from mere postulates to
substantiating evidences supporting its activity against gluta-
mate-mediated neurotoxicity [12], which has long been pin-
pointed as a major contributor in the pathogenesis of AD
[13,17,18]. Among the many proposed modes of action of
memantine, the most widely accepted and evidenced is
NMDA receptor antagonism, which has been further described
as low-affinity, uncompetitive, voltage-dependent, open-
channel, as well as partial trapping, block by separate studies.
Memantine performs this antagonism by blocking the channels
activated by NMDA receptor stimulation, the excessive acti-
vation of which mediates calcium-dependent neurotoxicity
associated with hypoxic-ischemic brain injury, trauma,
epilepsy, and neurodegenerative diseases [13]. In 1992, Chen
et al. [13] used whole-cell and single-channel recordings with
patch electrodes to study NMDA-induced currents on fluo-
rescently labeled, postnatal rat retinal ganglion cells (phar-
macologically similar to other central neurons) and concluded
that memantine selectively inhibits NMDA-elicited current
through the mechanism of open-channel block [16, 19]. This is
further supported by its voltage and agonist dependence.
Unlike dizocilpine (MK-801), a similar but older open-
channel blocker that protects neurons but also impairs manynormal neuronal functions and triggers reversible neuronal
swelling at therapeutic concentrations, memantine is clinically
well-tolerated at such concentrations, allowing it to even
inhibit NMDA receptor-mediated neurotoxicity in rat and
retinal ganglion cell neurons [13]. At low micromolar
concentrations, memantine is an uncompetitive antagonist and
(theoretically) allows near-normal physiological NMDA
activity throughout the brain even in the presence of high
concentrations of glutamate, an advantage that retains organ
functionality unique to memantine. Its distinctive rapid-
response kinetics also allows substantial NMDA receptor
function, even in areas with damaged neurons. These phar-
macological properties confer, to memantine, a therapeutic
advantage against NMDA receptor-mediated neurotoxicity,
with fewer observable side effects compared to other organic
NMDA open-channel blockers [13]. Furthermore, memantine
was found to be target-specific; it does not affect other types of
currents such as the kainate and quisqualate-activated currents,
save for the NMDA subtype. In the same study, Chen et al.
[13] also discovered, through electrophysiology experiments,
that at escalating levels of EAAs (excitatory amino acids or
glutamate carriers), the proportion of current inhibited by
memantine increases while basal level NMDA-induced
response remains consistent, unlike MK-801, which blocks
all NMDA-induced currents for longer periods and has
a slower unblocking rate than memantine [16]. Whereas early
increases in Ca2þ are associated with delayed-onset NMDA
receptor-mediated neurotoxicity, the presence of 6 mM mem-
antine is able to prevent excessive Ca2þ influx generated by
200 mM NMDA, indicating that it can avert this event by
allowing only basal NMDA receptor-mediated responses and
blocking excessive NMDA-elicited activity [13].
In the presence of NMDA, it takes memantine approxi-
mately 5.2 seconds to dissociate from NMDA receptor
channels at a holding potential of -60 mV, but pre-exposure to
3 mM magnesium eliminates this slow unblocking phase,
suggesting a possible binding site within the channel pore or
close enough to interact with the Mg2þ binding site [1,14,19].
Whole cell recordings in a 1997 study using cultured rat
cortical neurons or Chinese hamster ovary (CHO) cells
expressing NMDA receptors, also showed that memantine
blocks NMDA-activated channels [14] by binding to a site at
which it could be trapped after channel closure and agonist
binding [1, 15]. When memantine was washed off, one-sixth
of the blocked channels released the drug, exhibiting “partial
trapping” and a lower tendency to be trapped than phenycy-
clidine or MK-801. The same was observed with recombinant
NMDA receptors composed of NR1 and either NR2A or
NR2B subunits, suggesting that the partial trapping was not
due to the variability in memantine action on a heterogeneous
population of NMDA receptors in cortical neurons. To further
assess this phenomenon, Blanpied et al. used a simple kinetic
model of blocker action to show that partial trapping can result
if the presence of memantine in the channel affects the gating
transitions or agonist affinity of the NMDA receptor [15]. This
partial trapping ensures that the blocker will be released by
some channels between synaptic responses during synaptic
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the channel from closing while blocked, memantine is
a “trapping channel blocker”, which permits channel closure
and agonist dissociation while still bound in the channel.
Conformational changes involved in gating could sterically
prevent the exit of a trapping channel blocker out of the
channel, while the binding of a sequential blocker seals the
movement of the channel gate completely [15]. Low-to-
moderate affinity blockers, like memantine, are capable of
antagonizing the neurotoxic effects of continuous but rela-
tively small increases in glutamate concentration, but, like
Mg2þ [12], exit the NMDA channel following transient
physiological activation, due to the pronounced depolarization
of the postsynaptic membrane induced by high concentrations
of synaptically released glutamate [1,16].
Another target site for memantine that could possibly
contribute to its clinical importance is the dopamine D2high
receptor. Despite its NMDA antagonistic character, memantine
has been known to elicit dopamine action indirectly and
stimulate dopamine receptors, suggesting that it may have
similar potencies for the NMDA receptor and the high-affinity
state of the dopamine D2 receptor [20]. Upon testing this
hypothesis, Seeman et al. (2008) [20] found that memantine
(200e2000 nM) inhibited the release of prolactin, which is
controlled by dopamine D2 receptors, from the lactotrophs in
rat anterior pituitary cells. Potency of memantine at the
dopamine D2high receptor was also found to be similar, if not
greater, than at the NMDA receptor; hence the authors claim
that the lack of memantine action on actual serum prolactin
from elderly individuals (reported by a different study) may be
due to a balanced and simultaneous action on NMDA and D2
receptors, because glutamate pathways could alter the release
of prolactin. Similarly, memantine has been reported to inhibit
responses from human alpha7, alpha4/beta2, and alpha9/
alpha10 nicotinic receptors, as well as human and murine
5-HT3 receptors, with more or less similar magnitude to
NMDA receptors, although some of these actions are highly
unlikely to be of therapeutic relevance [1,19,21]. Nevertheless,
more studies are needed to verify these alleged possible
components of memantine action.
Aside from antagonizing NMDA receptors, memantine has
also been reported to block the increase in Ca2þ and oxidative
stress induced by Ab oligomers (ADDLs) [8]. ADDLs are
thought to induce ROS production in mature hippocampal
neurons and bind to neurons through a protein receptor
complex-mediated manner that involves NMDA receptors. In
an attempt to describe the mechanism of memantine action in
terms of neuroprotection, de Felice et al. [8] tested the potency
of memantine against soluble Ab oligomers, and found that at
therapeutically relevant doses, it can potently inhibit ADDL-
induced ROS formation but cannot prevent ADDL binding
to hippocampal neurons, hinting that ADDLs may not bind
directly to the NMDA receptor channel pore. Memantine
proved equally effective in blocking ADDL-induced Ca2þ
increase, implying that one likely mechanism of action of
memantine in AD is protection against neuronal oxidative
damage initiated by ADDLs.Recently, a dual action of memantine in AD was proposed
from a biomolecular perspective. Wu and Chen (2009) [7]
hypothesized that memantine not only antagonizes NMDA
receptors but may also act as an inhibitor of the internal
ribosome entry site (IRES), following an observation that it
inhibited IRES-mediated translation initiation in COS-1 cells.
This IRES inhibition, in turn, presumably prevents the
expression of amyloid precursor protein and tau proteins in
neurons, thereby relieving the symptoms of AD in an entirely
different manner. Structure-wise, memantine is similar to its
relative amantadine, which can legitimately block the IRES-
mediated translation of some viruses, hence forming the
basis for their assumption. Although it presents a distinct and
novel view on the mechanism of action of memantine, this
hypothesis, however, is yet to be verified by subsequent
studies. In Fig. 2, we summarized the “dual” working mech-
anism of memantine on AD.
Under therapeutic conditions, serum levels in man with
daily maintenance doses of 20 mg range from 0.5e1.0 mM,
while free cerebrospinal fluid (CSF, man) and brain micro-
dialysate (rat) levels are 20e50% lower due to albumin
binding in serum [14]. However, despite the fact that brain
homogenates in both man and rodents contain higher mem-
antine concentrations due to lysosomal accumulation, this in
no way reflects free concentrations found at CNS receptors
in vivo. Based on previous microdialysis studies and the
rationale that between man and rat: (1) drug sensitivity is
pharmacokinetics-related; (2) serum/brain ratio is similar; and
(3) 5 mg/kg is the dose where peak serum concentrations at
20e30 minutes are at the upper limit of those seen in serum
from patients and healthy volunteeers, it was proposed that
5 mg/kg i.p. in rats should be the maximum therapeutical
concentration for memantine needed to treat dementia,
notwithstanding other factors that affect pharmacokinetics,
such as age, strain, gender, and animal health status [14]. Since
repetitive administration in rats produces substantial fluctua-
tions in brain concentrations, while steady-state levels can be
found in chronically treated patients, s.c. infusion by Alzet
minipumps to mimic the pharmacokinetics seen in patients,
has been suggested for animal studies [14]. Memantine treat-
ment of 20 mg/kg/day, equivalent to 0.4e0.7 mM plasma
levels in the CNS as assessed by microdialysis, leads to
plasma levels ofw1 mM and does not affect spatial learning in
normal rats. Treatment, using the abovementioned concentra-
tions in rat and man, is sufficient to achieve brain levels that
affect NMDA receptors; however, higher doses are likely to be
selective at NMDA receptors and side effects may emerge at
acute doses of 20 mg/kg i.p. [14].
Clinical studies and safety
As claimed by numerous studies [4,12e17,19,22,23],
memantine is clinically well-tolerated unlike other neuro-
protective drugs of its kind, such as MK-801. During its entire
15-year clinical history, reported side effects have been
sporadic and memantine continues to be widely accepted as
a well-tolerated medication to this day [14]. In a population of
Fig. 2. The “dual” working mechanism of memantine on Alzheimer’s disease. The memantine ( ) can block the NMDA receptor and inhibit neurotoxicity induced
by glutamate. Memantine may also inhibit the Tau and APP proteins translation mediated through IRES in the mRNA of Tau and APP.
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dementia, memantine use was associated with improvement in
global assessments and functional capacities with decreasing
care-dependence [17]. Clinical data also indicate that mem-
antine is a useful treatment for AD, as symptomatological
improvements in cognitive processes, daily activities, and self
care are observable. Considering abuse potential, memantine
has shown satisfactory results in various animal studies: it did
not affect rats trained to distinguish cocaine, failed to poten-
tiate lateral hypothalamic self stimulation in contrast to
MK-801, exhibited zero effect on threshold frequency and
motor performance at 5 mg/kg (considered therapeutically
relevant) [12,14], and produced no motivational effects at
a dose of 7.5 mg/kg. Likewise, there are no reports of human
abuse [14] since the start of its use as medication.
Memantine owes its safety to the faster kinetics of action it
exhibits with rapid blocking and unblocking rates (unique
rapid-response kinetics) at low micromolar concentrations
proven to be clinically well-tolerated by patients with
Parkinson’s disease [13]. In an in vivo study performed by
Chen et al. (1992) [13], 20 mg/kg memantine did not produce
lethargy or other behavioral effects in a rat model, but pro-
tected neurons from damage. This is further proof of its safety
and efficacy. In neurotoxicity experiments of the same study,
6e12 mM memantine showed enough potency to prevent
NMDA receptor-mediated neuronal injury brought about by
excessive Ca2þ and low magnesium concentrations in both rat
retinal ganglion cells and cortical neurons [14]. However,
memantine has also been known to cause psychotomimetic
effects [19], if the recommended titration of dosing from 5 to
20 mg over 3e4 weeks is skipped or when combined with
dopaminomimetic therapies [14]. Memantine-triggered side
effects characteristic of NMDA receptor antagonists were also
found to be more evident in rats at acute doses (20e30 mg/kg)
than those considered therapeutically relevant, pointing out
that the difference between memantine and other NMDA
receptor antagonists is quantitative rather than qualitative. On
the other hand, it should also be noted that neuroprotectivedoses that inhibit the progression of chronic neurodegenerative
disorders, such as AD, are believed to be low and should not
be based on inapposite models such as acute ischemia, which
are generally severe in nature and require higher doses of
NMDA receptor antagonists [14].
Clinical studies, especially of sensitive drugs such as
memantine, require long-term, placebo-controlled studies with
large numbers of patients [14]. However, instead of evaluating
the effects of memantine on the progression of AD, clinical
studies have focused on defining symptomatological improve-
ment in late-stage AD patients. Despite this, the efficiency of
memantine cannot be doubted, as it is supported by numerous
studies such as the 1993 study, where symptomatological
improvement observed in demented patients did not decline
over a 12 month, non-placebo-controlled follow-up period
[14]. However, it was not until 2004 that a randomized, double-
blind, placebo-controlled 24-week clinical trial of patients
with moderate to severe AD (already receiving donepezil) was
conducted using memantine as treatment. Tariot et al. [22]
divided 404 patients into placebo and memantine groups and
noted that patients from the latter group received statistically
significant benefits and scored better on both CIBIC-Plus
(clinician’s interview-based impression of change plus) and the
BGP (behavioral rating scale for geriatric patients) care
dependency subscale than the first group using the LOCF (last
observation carried forward) approach. This demonstrated the
efficacy and tolerability of combining memantine and an
acetylcholinesterase (AChE) inhibitor. In terms of total NPI
score, patients in the memantine group fared worse than the
placebo group, indicating fewer behavioral disturbances and
psychiatric symptoms [22]. Furthermore, compared with the
memantine group, more participants from the placebo group
discontinued due to adverse effects, mainly confusion and
headache, although the confusion experienced by patients
receiving memantine were rated as mild, occured at a median of
32 days, and remitted within 2 weeks. Doody et al. (2004) [4]
also reported similar benefits, with moderate to severe AD
patients treated with memantine experiencing significantly less
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those receiving placebo. Memantine also appeared to promote
functional efficacy, with patients exhibiting improvement in
tasks such as standing up, moving, dressing, eating, taking in
fluid, and using the toilet, proving that it can also confer
noncognitive benefits in AD patients [4,22]. With regard to
behavior, a reducing effect of memantine on agitation/aggres-
sion was also observed, signifying a possibility of reducing
concomitant medications, which may lead to lesser resource
utilization and health costs [24]. In 2006, Dantoine et al. [23]
conducted a prospective, multicenter, open-label study
wherein patients under AChE inhibitors such as donepezil or
galantamine were switched to rivastigmine for 16 weeks, and
those who failed to stabilize were given memantine (5 mg/day)
as supplement. Of the 202 patients tested, 86 patients under-
went rivastigmine/memantine treatment with satisfactory
improvement on MMSE (Mini-Mental State Examination)
results and stability, illustrating the advantage of combining
AChE inhibitors, which are used for mild to moderate AD, and
memantine, which is recommended for moderate to severe AD
[23]. Despite adverse events reported, such as vomiting and
nausea, favorable safety and tolerability profiles for riva-
stigmine and memantine were established due to the high mean
doses reached (10.3 and 19.0 mg/day, respectively) and the
relatively low discontinuation rates caused by adverse effects
(e.g., vomiting, nausea). Hence it is safe to say that memantine
monotherapy or combination therapy has proven itself harmless
as well as beneficial.
Efficacy
According to Danysz et al. [12], NMDA receptor antago-
nists like memantine, which is capable of simultaneously
preserving physiological transmission while decreasing path-
ological activation [19], provide advantages such as hampering
disease progression and improving cognitive processes, espe-
cially when used at the early stages [12]. During the advanced
stages of AD, when secondary neurodegeneration is likely to
occur due to disinhibition, memantine is more effective than
other drugs because of the protection it exerts on neurons,
that allows physiological activation of NMDA receptors on
functional neurons to remain intact. The effectiveness of
memantine compared to agents like MK-801, lies in its
magnesium-like mode of action, which can help stabilize
neuronal activity at NMDA-receptor-bearing synapses at the
later stages of AD. Aside from offering neuroprotection and
stability, memantine is also increasingly effective against the
escalating levels of glutamate evident during a stroke even at
low micromolar concentrations. This was proven in a study
done by Chen et al. [13], wherein memantine at 6 mM pre-
vented retinal ganglion cell death from the endogenous
glutamate-related toxin in a dose-dependent manner, with
complete salvage of neurons [13], whereas amantadine
required much higher concentrations to achieve this. At 12 mM,
memantine sufficiently inhibited 200 mM NMDA-activated
currents [13] in a voltage-dependent manner [14e16], while
steady-state inhibition was achieved within 1 second of drugapplication and was agonist-dependent, i.e., it occurred only in
the presence of NMDA.
Memantine, along with ketamine and (þ)-MK-801, has also
been found to be 3-fold less potent against NMDA-induced
currents in freshly dissociated striatal neurons, but highly
effective on hippocampal neurons (involved in memory
formation), antagonizing current responses in a selective,
concentration-dependent manner [16]. Because memantine is
more effective on non-striatal structures, it exhibits a somewhat
inferior clinical profile in Parkinson’s [16] than its relative
amantadine and vice versa in AD. However, a reduced effect of
memantine on NMDA responses of striatal neurons, as
observed by Parsons et al. (1996) [16], indicates that a subclass
of NMDA receptors with altered relative voltage-dependency
of channel blockade is expressed in the striatumda premise
supported by a finding that memantine-sensitive NMDA
receptor-mediated excitatory postsynaptic potentials can be
recorded in the striatum in the presence of Mg2þ [16]. Other
factors that could influence the therapeutic effect of memantine
in in vitro studies, aside from the type of neuron, are the extent
to which it is trapped after channel block, the splice variants of
the receptor present in the neurons (e.g., NR1, NR2A, etc.)
[19], and the Csþ ions majorly used in patch clamp experi-
ments, that lower the affinity of memantine as an NMDA
receptor antagonist by increasing voltage-dependency [14].
Therefore, despite positive results, the effects of memantine
reported in studies are only mere estimations and not real or
actual measures of efficiency. Nevertheless they serve to give
us an idea of the potential possessed by memantine.
Upon testing the potency of memantine with intracellular
Kþ, Parsons et al. [16] observed a 2.6-fold increase in mem-
antine efficiency when Kþ is the major intracellular cation.
Memantine was also found to be more potent at NMDA
receptor subtypes expressed in HEK-293 and CHO cells, as
well as native NMDA receptors in freshly dissociated hippo-
campal neurons, all of which lack the large dendritic arbori-
zation of cultured hippocampal pyramidal neurons [15].
According to Parsons et al. [14,21], in vitro slice preparations,
used for electrophysiological recordings, also affect the activity
of memantine and other uncompetitive antagonists, because
lipophilic substances penetrate slowly into thick slices, and
blockade by uncompetitive NMDA receptor antagonists is use-
dependent [15,16]. They also mention in their review, a 1994
study which reported that higher doses of memantine are
required to block spinal neuron response to microiontophoretic
NMDA, and in a separate study done by the same group,
memantine was found to be much less effective against stronger
intensity responses from the same neurons. On the other hand,
memantine blocked glutamate-induced toxicity in differenti-
ated SHYSY5Y cells with an IC50 of 2.1 mM, in cultured
hippocampal neurons with an IC50 of 1.1 mM, and protected
cultured cortical neurons from the toxic effects of glutamate
with an IC50 of 1.4 mM, showing great promise as a neuro-
protective drug treatment. Parsons et al. [14] also conducted
a study which showed that the combined action of memantine
and a glycineB antagonist exhibits a better therapeutic profile
than MK-801 and a competitive NMDA receptor antagonist.
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weeks has been reported to prevent death, convulsions, and
hippocampal damage induced by i.c.v. quinolinic acid.
Malonate-induced striatal lesions were also attenuated by
memantine, proving its potential in treating chronic neurode-
generative diseases associated with deficits in mitochondrial
function [14]. Of particular relevance to the clinical use of
memantine are preclinical studies on the neurotoxic effects of
glutamate in structures known to be affected in AD, such
as the cholinergic nucleus basalis of Meynert (NBM, or
nucleus basalis magnocellularis in rats) [12, 14]. In successive
studies done by Wenk et al. (1994, 1995, 1997) [26e28],
memantine, at a dose considerably lower than that which
causes side effects, given i.p. before NMDA microinjection,
produced dose-dependent protection and resulted in plasma
levels similar to those in patients given therapeutic doses. In
a T-maze alternation task, memantine pretreatment also
proved useful in antagonizing the learning deficits induced by
microinjection of NMDA into the NBM [12,14]. It also pre-
vented lesions in the NBM from forming, due to mitochondrial
toxin 3-NP injection [12]. In 1996, a follow-up study was
performed, to assess two important features disregarded in the
abovementioned series of studies, namely, that the insult was
of an acute nature and not progressive, and that memantine
was administered as a bolus injection that does not mimic the
steady-state levels observed in patients [14]. After incorpo-
rtating the necessary adjustments, memantine was shown to
still enable rats to function normally in the T-maze, while
those infused with quinolinic acid had clear learning deficits
and had reduced choline uptake sites (indicator of the density
of ACh terminals) in the cortex [12,14]. Memantine, however,
exerted no effect on T-maze learning, LTP (long term poten-
tiation, an elementary feature of neuronal memory formation)
in hippocampal slices ex vivo, or LTP in the dentate gyrus in
normal rats in vivo [14].
Nakamura et al. (2006) [25] also examined the effects of
memantine on learning, by injecting Ab and ibotenic acid in to
the hippocampus of rats and using the mean escape latency
during the water maze task as a gauge. Similar to other studies,
injected rats exhibited better performance with memantine as
opposed to MK-801, proving the superior inhibitory ability of
memantine against cognitive deficits over MK-801. In terms of
memory impairment, memantine was also useful in restoring
or enhancing spatial memory in rat models. Zajaczkowski et
al. (1997) reported that memantine also has the ability to
antagonize NMDA-induced amnesia at doses  5 mg/kg in
rats [29]. In separate experiments, memantine was able to
prevent LTP reduction induced by non-toxic concentrations of
NMDA and the removal of magnesium, leading to the
conclusion that under tonic activation of NMDA receptors,
memantine can restore LTP induction and reverse deficits in
synaptic plasticity, both at the neuronal and behavioral level
[12,17]. Yamada et al. [30] demonstrated that memantine
could prevent the development of Ab-induced memory
impairment in rats using the delayed-matching to position task
(DMTP) and bilateral injections of Ab1-40 into the hippo-
campus, while memantine/donepezil combination treatmentproduced no synergistic effects due to a ceiling effect. Mem-
antine was also able to enhance hippocampal spatial learning
in a transgenic mouse model of AD, despite its inability to
produce nonspecific effects on locomotion/exploratory activity
[31]. Zoladz et al. [32], however, reported that although
memantine produced some significant influence on the
improvement of long-term spatial memory, neramexane,
a fellow uncompetitive NMDA receptor inhibitor, showed
more potency than memantine.
Because of mounting evidence that inflammation, especially
in the NBM, is a contributory factor in neurotoxicity in AD [12,
14], a 1998 study developed a chronic brain inflammation
model using lipopolysaccharide (LPS) as the inflammatory
trigger in the NBM. Using therapeutically relevant doses of
memantine (20 mg/kg/day) [14,19] provided significant neu-
roprotection from LPS, but did not affect the inflammatory
reaction [12,14]. This result, nevertheless, illustrates the neu-
roprotective influence of memantine in treating demented
patients. Hence, if the contribution of NMDA receptors in the
neuropathology of AD is accepted, then memantine could
possibly slow down the progression of this disorder [12,14].
In humans, clinical studies have also shown the efficacy of
memantine through placebo-controlled trials with patients
diagnosed with moderate to severe AD, employing cognitive,
functional, and global outcome measures as a basis for
assessment. In 2004, Doody et al. [4] conducted a study based
on previous works, and enumerated the specific functional
effects of memantine treatment observable in AD patients.
Remarkable reduction in decline of ADL skills, such as
making conversation, disposing of litter, using the toilet, and
getting around outside of one’s home, were documented, with
patients under memantine monotherapy scoring better in tests
assessing functional capacity than those in the placebo control
group. Similarly, Tariot et al. (2004) [22] reported better
scores for donepezil/memantine-treated patients in tests which
evaluated cognitive dysfunction and late-stage dementia than
for placebo-treated ones. Gauthier et al. [24] also confirmed in
an auxiliary study to Tariot et al. that memantine was able to
confer behavioral benefits to AD patients, alleviating neuro-
psychiatric symptoms associated with dementia, most notably
agitation/aggression. A responder analysis done in 2006, also
reported that memantine treatment while under donepezil
yielded positive effects on cognitive improvement, stabiliza-
tion of outcome scores, as well as risk reductions for all
combinations of outcome measures [18]. Supplementing
memantine for rivastigmine treatment also decelerated cogni-
tive and behavioral deterioration in patients with moderate to
severe AD [23] without significant adverse effects, demon-
strating that memantine is both safe and effective to use in
monotherapy or combination therapy.
Conclusion
AD is a progressive disease, the treatment of which is
a critical issue worldwide. The main causes of AD are said to
be the aggregation of b-amyloid peptides into senile plaques
and the fibrillization of hyperphosphorylated tau proteins into
422 E. Dominguez et al. / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 415e423neurofibrilliary tangles, both of which lead to neuro-
degeneration. Recently, however, mitochondrial malfunction
and oxidative stress have also been pinpointed as factors that
affect the neuronal cascade that leads to AD. However, the
most studied cause of this disease is excitotoxicity. Excito-
toxicity is a pathological process that damages and kills
neurons due partly to the overactivation of NMDA receptors
that permit excessive Ca2þ influx. Because excitotoxicity is
usually associated with the pathophysiology of chronic
neurodegenerative disorders, it has become an attractive target
for neuroprotective efforts. Memantine is a low-to-moderate
affinity, uncompetitive, voltage-dependent, open-, as well as
partial trapping, channel blocker; its mechanism of action is
NMDA receptor antagonism. Memantine has been proven to
be more effective in numerous studies than other channel
blockers such as MK-801, in providing neuroprotection and
inhibiting NMDA-induced currents in vivo. Another advantage
of memantine is its ability to allow near-normal physiological
NMDA activity throughout the brain, even in the presence of
high levels of glutamate, thus retaining organ functionality.
Due to this, and distinctive rapid-response kinetics, mem-
antine offers a better therapeutic advantage against NMDA
receptor-mediated neurotoxicity with fewer side effects than
other conventional open-channel blockers. Memantine has
also been shown to block the increase in Ca2þ and oxidative
stress brought about by ADDLs, by inhibiting ADDL-induced
ROS formation. Aside from this, it has also been hypothesized
to inhibit the IRES, which presumably prevents the expression
of amyloid precursor protein and tau proteins, thereby
relieving the symptoms of AD. Despite the number of studies
conducted with regard to memantine’s mechanism of action
against the identified causes of AD, more evidence and further
probing is needed in order to establish its exact mode of
action.
In terms of safety for clinical use, memantine has been
found to be well-tolerated on many occasions. Clinical data
also indicate that memantine use produced significant
improvements in global assessments and functional capacities,
as well as symptomatological improvements in cognitive
processes, daily activities, and self-care of AD patients.
Memantine has a very low abuse potential, has shown satis-
factory results in various animal studies, and boasts no report
of human abuse throughout its medical history. Memantine
treatment in patients with moderate-to-severe AD, also
conferred substantial benefits, i.e., better scores on various
cognitive- and non-cognitive-related tests, reduced behavioral
disturbances and psychiatric symptoms, improved functional
efficacy, and fewer and more tolerable side effects than other
drugs, be it in monotherapy or combination therapy with
acetylcholinesterase inhibitors. Memantine also produced
favorable safety and tolerability profiles in animal models and
was effective in reversing deficits in synaptic plasticity,
demonstrating its huge potential in alleviating the symptoms
of AD. Hence, if the exact mechanism of action of memantine
can be pinpointed, the full potential of memantine can be used
and, combined with proper usage, memantine can ultimately
be utilized for the complete treatment of AD.References
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